Taking stock of advances in clinical recognition, laboratory testing, and pharmacologic therapy as well as basic aspects of pathogenesis, the Third Edition of Heparin-Induced Thrombocytopenia reinforces its standing as the leading guide to accurate diagnosis and effective management of this complex condition. Featuring added chapters on bivalirudin and pediatric heparin-induced thrombocytopenia (HIT), this reference also updates all 20 chapters of the previous edition to regard anew such topics as management of HIT using direct thrombin inhibitors and the special problems of renal failure and cardiac surgery in HIT patients.
Author(s): Theodore E. Werkentin, Andreas Greinacher
Edition: 3
Year: 2003
Language: English
Pages: 350
Series Introduction......Page 9
Preface to the Third Edition......Page 11
Preface to the Second Edition......Page 13
Preface to the First Edition......Page 15
Contents......Page 21
Contributors......Page 25
History of Heparin-Induced Thrombocytopenia......Page 29
Differential Diagnosis of Acute Thrombocytopenia......Page 53
Clinical Picture of Heparin-Induced Thrombocytopenia......Page 81
Frequency of Heparin-Induced Thrombocytopenia......Page 139
Nonimmune Heparin–Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia......Page 181
Heparin-Dependent Antigens in Heparin-Induced Thrombocytopenia......Page 197
Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia......Page 211
Role of Sulfated Polysaccharides in the Pathogenesis of Heparin-Induced Thrombocytopenia......Page 229
The Platelet Fc Receptor in Heparin-Induced Thrombocytopenia......Page 255
Immune Vascular Injury in Heparin-Induced Thrombocytopenia......Page 283
Laboratory Testing for Heparin-Induced Thrombocytopenia......Page 303
Pseudo–Heparin-Induced Thrombocytopenia......Page 345
Treatment of Heparin-Induced Thrombocytopenia: An Overview......Page 367
Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia......Page 403
Lepirudin for the Treatment of Heparin-Induced Thrombocytopenia......Page 429
Argatroban Therapy in Heparin-Induced Thrombocytopenia......Page 469
Bivalirudin for the Treatment of Heparin-Induced Thrombocytopenia......Page 507
Hemodialysis in Heparin-Induced Thrombocytopenia......Page 541
Management of Cardiopulmonary Bypass Anticoagulation in Patients with Heparin-Induced Thrombocytopenia......Page 563
Heparin-Induced Thrombocytopenia in Children......Page 585
Legal Aspects of Heparin-Induced Thrombocytopenia: U.S. Perspectives......Page 605
Legal Aspects of Heparin-Induced Thrombocytopenia: European Perspectives......Page 619
Appendixes......Page 627
APPENDIX 1. TEN CLINICAL ‘‘RULES’’ FOR DIAGNOSING HIT......Page 629
APPENDIX 2. ESTIMATING THE PRETEST PROBABILITY OF HIT: THE FOUR T’S......Page 631
APPENDIX 3. PLATELET COUNT MONITORING FOR HIT......Page 632
APPENDIX 4. TREATMENT RECOMMENDATIONS*......Page 634
APPENDIX 5. DANAPAROID DOSING SCHEDULES IN HIT PATIENTS......Page 638
APPENDIX 6. DOSING SCHEDULES FOR LEPIRUDIN TREATMENT OF PATIENTS WITH HIT......Page 640
APPENDIX 7. DOSING SCHEDULE FOR LEPIRUDIN IN PATIENTS WITH HIT AND RENAL IMPAIRMENT......Page 642
APPENDIX 8. DOSING SCHEDULES FOR ARGATROBAN TREATMENT OF PATIENTS WITH HIT (APPROVED INDICATIONS)......Page 643
APPENDIX 9. TIMELINES OF AN EPISODE OF HIT......Page 644
Index......Page 645
